Since 1981, when it was founded as a small start-up in Boston, Genzyme has evolved into a diversified global business with annual revenues exceeding $2 billion. Over the past two decades, Genzyme has introduced a number of breakthrough treatments in several areas of medicine. These therapies provide hope to patients who previously had no viable treatment options.

Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. More than 25 marketed Genzyme products are helping people in 80 countries. The company's headquarters are in Cambridge, Massachusetts, in the United States.

Genzyme Genetics, a business unit of Genzyme Corporation, has added Bone Marrow Engraftment (Chimerism) Analysis by polymerase chain reaction (PCR) to its extensive cancer diagnostic/prognostic testing services.